Regeneron Pharmaceuticals, Inc. (REGN) is listed on NASDAQ in Pharmaceutical Stocks. It is $794.08, -1.69%, with a $82.1B market cap. RSI is 58.2, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 58.2 Neutral
Market Cap $82.1B
P/E Ratio 41.9x
Volume 496.3K
Fundamentals — 10-Q Q2 2026
Revenue $7.9B
Net Income $2.0B
EPS $18.95
Operating Margin 24.5%
Net Margin 25.6%
Debt / Equity 0.1x
P/E Ratio 41.9x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Guarini Kathryn | Director | Sell | 400 | $800.00 | $320,000 | 2026 Aug 10 |
| Zoghbi Huda Y | Director | Sell | 800 | $800.00 | $640,000 | 2026 Aug 10 |
| Ryan Arthur F | Director | Sell | 200 | $650.15 | $130,030 | 2026 Jul 2 |
| Ryan Arthur F | Director | Sell | 100 | $705.24 | $70,524 | 2026 May 1 |
| Ryan Arthur F | Director | Sell | 100 | $777.27 | $77,727 | 2026 Apr 1 |
| Ryan Arthur F | Director | Sell | 100 | $785.50 | $78,550 | 2026 Mar 2 |
| Zoghbi Huda Y | Director | Sell | 1,638 | $781.33 | $1.3M | 2026 Feb 19 |
| Bassler Bonnie L | Director | Sell | 760 | $750.00 | $570,000 | 2025 Nov 20 |
| Pitofsky Jason | VP Controller | Sell | 431 | $651.43 | $280,766 | 2025 Nov 7 |
| Poon Christine A | Director | Sell | 6,500 | $654.27 | $4.3M | 2025 Oct 29 |
| McCourt Marion | EVP Commercial | Sell | 1,000 | $844.61 | $844,610 | 2024 Nov 1 |
| McCourt Marion | EVP Commercial | Sell | 1,000 | $1054.06 | $1.1M | 2024 Oct 1 |
| Ryan Arthur F | Director | Sell | 100 | $1048.78 | $104,878 | 2024 Oct 1 |
| McCourt Marion | EVP Commercial | Sell | 1,000 | $1178.73 | $1.2M | 2024 Sep 3 |
| Ryan Arthur F | Director | Sell | 100 | $1178.68 | $117,868 | 2024 Sep 3 |
| Fenimore Christopher R. | SVP Finance & CFO | Sell | 5,680 | $1205.33 | $6.8M | 2024 Aug 28 |
| Bassler Bonnie L | Director | Sell | 756 | $1170.00 | $884,520 | 2024 Aug 15 |
| Poon Christine A | Director | Sell | 10,838 | $1158.17 | $12.6M | 2024 Aug 15 |
| Murphy Andrew J | EVP Research | Sell | 6,363 | $1153.15 | $7.3M | 2024 Aug 14 |
| Stahl Neil | EVP Research and Development | Sell | 5,197 | $1084.54 | $5.6M | 2024 Aug 8 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $45.60 | 41.8 | -- |
| | $27.96 | 64.8 | $159.3B |
| | $541.72 | 61.7 | $137.3B |
| | $112.44 | 58.9 | $195.8B |
| | $162.66 | 48.4 | -- |
Take REGN further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put REGN in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Regeneron Pharmaceuticals, Inc. next reports.
Set alerts on REGN
Get notified when Regeneron Pharmaceuticals, Inc. hits your price targets or technical conditions are met.
Get Started Free